Last reviewed · How we verify
dose 1 IBI302
IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response.
IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | dose 1 IBI302 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This leads to increased activation and proliferation of T-cells, which can recognize and kill cancer cells. IBI302 has shown promise in treating various types of cancer by enhancing anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration (PHASE1)
- A Study of IBI302 in Patients With nAMD (PHASE2)
- A Study of Longer Interval of IVT IBI302 in Subjects With nAMD (PHASE2)
- Evaluation of IBI302 Injection in nAMD or DME (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dose 1 IBI302 CI brief — competitive landscape report
- dose 1 IBI302 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI